Elixir Pharmaceuticals, Inc.
Elixir Pharmaceuticals concocts treatments targeting metabolic diseases and disorders. Dedicated to the discovery, development, and commercialization of treatments for such diseases as diabetes and obesity, the company has taken a dual approach to its work: licensing products from other pharmaceutical companies for development and pursuing proprietary products. Product candidates currently under development include Glinsuna and Metgluna as treatment for type 2 diabetes and a ghrelin antagonist as a treatment for a range of metabolic disorders (all in phase III testing). The company is also exploring the use of sirtuin modulators to treat metabolic disorders, cancer, and neurodegenerative disease.
Contact Details
Executives
Chairman
Vaughn M. Kailian
CEO and Chief Medical Officer
Paul M. (Kip) Martha